Postmarketing surveillance and reporting of adverse drug events.
作者信息
Baer Rebecca K
出版信息
S D J Med. 2004 Jan;57(1):13-4.
PMID:14964975
Abstract
摘要
相似文献
1
Postmarketing surveillance and reporting of adverse drug events.药品上市后监测及药品不良反应报告。
S D J Med. 2004 Jan;57(1):13-4.
2
Drug safety. Gaps in the safety net.药物安全。安全保障中的漏洞。
Science. 2005 Jan 14;307(5707):196-8. doi: 10.1126/science.307.5707.196.
3
Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.因果关系？评估上市后安全性研究作为产品责任案件中因果关系的证据。
Food Drug Law J. 2007;62(3):445-72.
4
FDA guidance document on monitoring delayed adverse events a good first start.
Mol Ther. 2005 Dec;12(6):991-2. doi: 10.1016/j.ymthe.2005.10.011. Epub 2005 Nov 3.
5
FDA attempting to overcome major roadblocks in monitoring drug safety.美国食品药品监督管理局正在试图克服药品安全监测中的重大障碍。
J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. doi: 10.1093/jnci/97.12.872.
6
Reform of drug regulation--beyond an independent drug-safety board.药品监管改革——超越独立药品安全委员会
N Engl J Med. 2006 Jan 12;354(2):194-201. doi: 10.1056/NEJMsb053432.
7
Postmarketing surveillance--lack of vigilance, lack of trust.上市后监测——警惕性不足，信任缺失。
JAMA. 2004 Dec 1;292(21):2647-50. doi: 10.1001/jama.292.21.2647. Epub 2004 Nov 22.
8
Vioxx's history and the need for better procedures and better testing.万络的历史以及对更好的程序和更完善测试的需求。
Seton Hall Law Rev. 2007;37(4):941-68.
9
Strategy for surveillance of adverse drug events.药品不良事件监测策略。
Food Drug Law J. 2007;62(3):605-16.
10
Xyrem (sodium oxybate) postmarketing adverse event reporting system.羟丁酸钠上市后不良事件报告系统。
Sleep Med. 2010 Jun;11(6):595; author reply 595-6. doi: 10.1016/j.sleep.2010.02.003. Epub 2010 Apr 1.
Zotero 插件